Vyvgart (efgartigimod alfa-fcab) is a first-in-class intravenously administered neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
If you have a Hayes login, click here to view the full report on the Knowledge Center.